LOSS OF HETEROZYGOSITY AT 12P12–13 IN PRIMARY AND METASTATIC PROSTATE ADENOCARCINOMA
- 1 July 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (1) , 192-196
- https://doi.org/10.1016/s0022-5347(05)67493-9
Abstract
Our laboratory has recently identified a 1 to 2 Mb homozygous deletion at 12p12–13 in a prostate cancer specimen and determined that the p27/kip1 gene lies within the deletion. While immunohistochemical analysis has implicated p27/kip1 in prostate carcinoma, no previous studies had identified genetic abnormalities at this locus. Here, we examined primary and metastatic prostate tumors to determine if allelic loss occurs at this locus in localized disease and if it increases the risk of metastatic, high stage or high-grade disease. DNA was extracted from prostate tumors and normal tissue of 99 patients. 60 tumors were primary, 20 were metastatic pelvic lymph nodes, and 19 were distant metastases. Multiple metastases were analyzed from 11 of 19 patients with metastatic disease. Polymorphic markers spanning our region of interest were PCR amplified from tumor and normal DNA. PCR products were then scored for allelic loss. Loss of heterozygosity (LOH) was identified in 14/60 (23%) primary tumors, 6/20 (30%) lymph node metastasis, and 9/19 (47%) distant metastases. The difference between primary and distant metastatic disease was statistically significant (p = 0.045, Fisher’s exact test). The pattern of LOH was identical in all metastatic sites obtained from individual patients, indicating that genetic loss occurred prior to metastasis. Subset analysis of the 60 primary tumors demonstrated no association between LOH and adverse pathological feature [nodal involvement, seminal vesicle invasion, margin positivity, high Gleason score (7–10)]. Demonstrating that 12p12–13 LOH is a prominent feature of primary prostate tumors and that multiple metastatic foci have an identical LOH pattern, provides evidence that gene inactivation in this region occurs prior to metastasis. In addition, the strong association between LOH and distant metastasis raises the possibility that mutational inactivation of a gene at 12p12–13, possibly p27/kip1, plays a pivotal role in the development of metastatic disease.Keywords
This publication has 14 references indexed in Scilit:
- Deletion mapping at 12p12-13 in metastatic prostate cancerGenes, Chromosomes and Cancer, 1999
- New insights into the tumor suppression function of P27 Kip1Proceedings of the National Academy of Sciences, 1998
- The murine gene p27Kip1 is haplo-insufficient for tumour suppressionNature, 1998
- Distinct Altered Patterns of p27KIP1 Gene Expression in Benign Prostatic Hyperplasia and Prostatic CarcinomaJNCI Journal of the National Cancer Institute, 1998
- Prostate Stem Cell CompartmentsThe American Journal of Pathology, 1998
- Genetic Alterations in Hormone-Refractory Recurrent Prostate CarcinomasThe American Journal of Pathology, 1998
- Association of p27Kipl Levels With Recurrence and Survival in Patients With Stage C Prostate CarcinomaJNCI Journal of the National Cancer Institute, 1998
- Cancer Cell CyclesScience, 1996
- Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocationCell, 1994
- Allelotyping of human prostatic adenocarcinomaGenomics, 1991